Der var ingen mærkbar forskel i incidensen af bekræftede alvorlige thrombotiske kardiovaskulære hændelser hos
There was no discernible difference in the rate of confirmed serious thrombotic cardiovascular events between patients receiving etoricoxib ≥ 60 mg, placebo, or non- naproxen NSAIDs.